secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lipocine Inc. (LPCN)
CIK:        0001535955
Form:       8-K
Filed at:   2026-01-20T23:59:59+00:00
Accession:  0001493152-26-002785
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lipocine completes Phase 3 enrollment for oral brexanolone in postpartum depression; topline data due Q2 2026
--------------------------------------------------------------------------------

- 90 patients randomized in double-blind, placebo-controlled Phase 3 trial of LPCN 1154 (oral brexanolone) for PPD.
- Safety profile favorable: no discontinuations, excessive sedation, loss of consciousness, or drug-related SAEs.
- Outpatient setting, no medical monitoring required; study incorporates FDA feedback.
- Topline efficacy and safety results expected early Q2 2026; NDA submission planned for 2026.
- LPCN 1154 could become first-line treatment for severe PPD, including elevated suicide risk.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1535955/000149315226002785/0001493152-26-002785-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1535955/000149315226002785/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-002785

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer